AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38253338
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of RSVPreF3 OA (first dose followed by revaccination)
Trial: 38253436
Drug: HEAVY (high-load,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEAVY (high-load, full-range, supervised twice/week)
Trial: 38253886
Drug: Diluted calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted calcium hydroxylapatite (CaHA; Radiesse®) administered via cannula-based subcision technique, total of 12 syringes, 1:1 dilution, across three treatment sessions
Trial: 38254137
Drug: Room air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room air at a flow rate of 2 L/min.
Trial: 38254147
Drug: Leap Motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leap Motion Controller® device combined with conventional therapy
Trial: 38254201
Drug: Oral 5-Aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-Aminolevulinic acid (5-ALA) concurrent to radiotherapy (RT) with a maximum of eight fractions of radiodynamic therapy (RDT).
Trial: 38254201
Drug: Oral 5-Aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-Aminolevulinic acid (5-ALA) concurrent to radiotherapy (RT).
Trial: 38254201
Drug: 5-ALA metabolites
RxNorm normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-ALA metabolites and radiobiological markers analysis throughout the course of therapy.
Trial: 38254211
Drug: Azvudine 5
RxNorm normalized name: Azvudine
DrugBank: Azvudine (DB16407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azvudine 5 mg daily for a maximum of 7 days
Trial: 38254211
Drug: Placebo (five
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (five tablets daily)
Trial: 38254233
Drug: Thoracic paravertebral
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic paravertebral block (TPVB) with 15 ml of 0.5% ropivacaine administered to T4 and T7 thoracic paravertebral spaces before general anaesthesia induction.
Trial: 38257071
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids, dosage and duration not specified
Trial: 38258329
Drug: Decitabine 20
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 20 mg/m² followed by cytarabine
Trial: 38258563
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg bolus of recombinant staphylokinase (r-SAK) before PCI
Trial: 38258673
Drug: Hip-focused physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip-focused physical therapy
Trial: 38258673
Drug: Spine-focused physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spine-focused physical therapy
Trial: 38258677
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (6 mg)
Trial: 38259250
Drug: Pelabresib (CPI-0610)
RxNorm normalized name: pelabresib
DrugBank: Pelabresib anhydrous (DB17129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelabresib (CPI-0610) 225 mg tablet QD
Trial: 38259304
Drug: Rivaroxaban therapy
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban therapy
Trial: 38260556
Drug: Febuxostat (XOI)
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat (XOI) treatment for 48 weeks
Trial: 39541169
Drug: Baricitinib 2
RxNorm normalized name: baricitinib 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 2 mg daily for 16 weeks
Trial: 38261092
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RV dysfunction with RV dilation or ACP
Trial: 38261313
Drug: Pralsetinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pralsetinib (400 mg once daily, orally)
Trial: 38261316
Drug: Avelumab at
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab at 10 mg/kg on days 1 and 15, ramucirumab at 8 mg/kg on days 1 and 15, paclitaxel at 80 mg/m2 on days 1, 8, and 15 every 4 weeks.
Trial: 38261323
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of naloxone (4 mg/0.1 mL) at 0, 2.5, 5, and 7.5 minutes
Trial: 38261323
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of naloxone at 0 and 2.5 minutes
Trial: 38261323
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of naloxone at 0 and 2.5 minutes (control)
Trial: 38261323
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of naloxone at 0, 2.5, 5, and 7.5 minutes (test)
Trial: 38261323
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of naloxone at 0 and 2.5 minutes (test)
Trial: 38261390
Drug: Modified remission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified remission glucocorticoid threshold (<5.0 mg/day prednisolone)
Trial: 38261392
Drug: Lupus anticoagulant
RxNorm normalized name: Lupus anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupus anticoagulant positivity at inclusion
Trial: 38261392
Drug: Triple antiphospholipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiphospholipid antibody positivity
Trial: 38261444
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg twice daily and Uprosertib starting at 50 mg daily (doublet cohort)
Trial: 38261444
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg twice daily, Trametinib 2 mg daily, and Uprosertib 75 mg daily (triplet cohort)
Trial: 38261579
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of azithromycin (20 mg/kg)
Trial: 38261893
Drug: Pharmacist-led program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led program for HCV treatment
Trial: 38261893
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral medications (DAAs) initiation
Trial: 38261893
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of DAAs treatment
Trial: 38261958
Drug: Camrelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (200 mg intravenously, day one) + Apatinib (250 mg, q.d., five continuous days per week) + Nab-paclitaxel (135 mg/m2)
Trial: 38262275
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low endothelial shear stress (ESS), high ESS gradient (ESSG), and high plaque structural stress (PSS) heterogeneity index (HI)
Trial: 38262275
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low ESS, high ESSG, and high PSS HI with plaque burden >70%
Trial: 38262428
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g intravenous once within 12 hours following tracheal intubation
Trial: 38263021
Drug: Amlodipine/benazepril 5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/benazepril 5/10 mg
Trial: 38263021
Drug: Benazepril/hydrochlorothiazide 10/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril/hydrochlorothiazide 10/12.5 mg
Trial: 38263053
Drug: Prehabilitation (structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehabilitation (structured exercise training, nutritional counselling/therapy, psychological support) 2-3 sessions/week for at least 4 weeks before surgery
Trial: 38263321
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg orally once a day and durvalumab 1500 mg once every 3 weeks
Trial: 38263486
Drug: EGFR BATs
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR BATs (anti-CD3 x anti-EGFR bispecific antibody armed T cells) in combination with radiation and temozolomide (TMZ)
Trial: 38263486
Drug: EGFR BATs
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR BATs at the maximum feasible dose of 80 × 10
Trial: 38263652
Drug: Intravenous iscalimab
RxNorm normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iscalimab (10 mg/kg)
Trial: 38264276
Drug: 5-mcg norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mcg norepinephrine
Trial: 38264276
Drug: 10-mcg norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mcg norepinephrine
Trial: 38264520
Drug: Enzalutamide as
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide as first line treatment for mCRPC
Trial: 38264632
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of oral psilocybin (first dose: 25 mg; second dose: 25 or 30 mg) paired with non-directive support
Trial: 38264697
Drug: CURATE.AI-assisted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CURATE.AI-assisted dose titration
Trial: 38264869
Drug: Rucosopasem 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucosopasem 100 mg
Trial: 38264938
Drug: Ultrasound-facilitated catheter-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-facilitated catheter-directed thrombolysis (USCDT) with mean alteplase (r-tPA) infusion duration of 10.5 hours and mean total r-tPA dose of 18.1 mg.
Trial: 38265029
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (prescribed to 30.8% of children)
Trial: 38265029
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic treatment (not prescribed to 69.2% of children)
Trial: 38265835
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg, once daily)
Trial: 38266104
Drug: Pexidartinib (CSF-1R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexidartinib (CSF-1R inhibitor)
Trial: 38266154
Drug: Low-titer inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-titer inhibitor progression to high-titer inhibitor
Trial: 38266332
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for anxiety and obsessive-compulsive disorders, 12 sessions
Trial: 38266482
Drug: Post-trigger LH
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-trigger LH levels < 22 IU/L
Trial: 38266482
Drug: Basal LH
RxNorm normalized name: LH-708
DrugBank: LH-708 (DB17636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal LH levels < 4 IU/L
Trial: 38266482
Drug: Post-trigger LH
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-trigger LH levels above 15 IU/L
Trial: 38266683
Drug: Apremilast (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast (20 or 30 mg BID based on weight)
Trial: 38267096
Drug: CRE infection
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRE infection vs CSE infection (with treatment-related variables)
Trial: 38267188
Drug: Glenzocimab 1000
RxNorm normalized name: Glenzocimab
DrugBank: Glenzocimab (DB16175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glenzocimab 1000 mg
Trial: 38267243
Drug: Ferric derisomaltose
RxNorm normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferric derisomaltose infusion
Trial: 38267243
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous succinate
Trial: 38267245
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBM) at a dose of 7.5 J/cm²
Trial: 38267330
Drug: 20-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-valent pneumococcal conjugate vaccine (PCV20)
Trial: 38267330
Drug: 23-valent polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent polysaccharide vaccine (PPSV23)
Trial: 38267942
Drug: Allopurinol administered
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol administered immediately after birth
Trial: 38268156
Drug: Metformin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (0.5 g three times per day)
Trial: 38268157
Drug: Secukinumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (150 mg to 300 mg dose escalation)
Trial: 38268221
Drug: Maternal vaginal
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal vaginal and rectal microbiomes during the last trimester
Trial: 38268752
Drug: Batoclimab 680
RxNorm normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batoclimab 680 mg QW for 12 weeks
Trial: 38268752
Drug: Batoclimab 340
RxNorm normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batoclimab 340 mg QW for 12 weeks
Trial: 38268752
Drug: Batoclimab 340
RxNorm normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batoclimab 340 mg QW or Q2W for maintenance
Trial: 38269045
Drug: Customized silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized silicone digital orthoses plus specialized nurse-administered foot care
Trial: 38269045
Drug: Specialized nurse-administered
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized nurse-administered foot care (Control Group)
Trial: 38270814
Drug: Chemotherapy, radiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy, radiotherapy, or immunotherapy
Trial: 38270822
Drug: Navitoclax 150
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax 150 mg daily plus Sorafenib 400 mg twice daily
Trial: 38271019
Drug: TranS-C group
RxNorm normalized name: meningococcal group C polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TranS-C group treatment
Trial: 38271308
Drug: Oral Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Assessment Guide (OAG) assessment
Trial: 38271308
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of oral care
Trial: 38272050
Drug: Individualised short-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised short-course antibiotic treatment (≤7 days, as short as 3-5 days)
Trial: 38272050
Drug: Short-course treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course treatment
Trial: 38272046
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (2 g/kg, single dose)
Trial: 38272046
Drug: Methylprednisolone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (10 mg/kg per day for 3 consecutive days)
Trial: 38272046
Drug: Tocilizumab (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (12 mg/kg for patients <30 kg; 8 mg/kg for patients ≥30 kg, max 800 mg)
Trial: 38272046
Drug: Anakinra (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (2 mg/kg once per day for patients ≥10 kg)
Trial: 38272046
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no additional treatments)
Trial: 38272373
Drug: Dupilumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab treatment in patients with biallelic pathogenic FLG variants
Trial: 38272373
Drug: Dupilumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab treatment in patients with monoallelic pathogenic FLG variants or wild-type alleles
Trial: 38272375
Drug: dupilumab 100/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dupilumab 100/200 mg by body weight or volume-matched placebo every 2 weeks for 52 weeks
Trial: 38272383
Drug: PPOS protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPOS protocol (Medroxyprogesterone 10 mg daily from start of ovarian stimulation until ovulation trigger)
Trial: 38272383
Drug: Antagonist protocol
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antagonist protocol (Antagonist 0.25 mg daily from the sixth day of ovarian stimulation until ovulation trigger)
Trial: 38272383
Drug: Antagonist protocol
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antagonist protocol (per-protocol analysis)
Trial: 38272555
Drug: High-cholesterol (600 mg)/low-saturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-cholesterol (600 mg)/low-saturated fat (6%) (egg) diet
Trial: 38272555
Drug: Low-cholesterol (300 mg)/high-saturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-cholesterol (300 mg)/high-saturated fat (12%) (egg free) diet
Trial: 38272555
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet that is high in both cholesterol (600 mg) and saturated fat (12%)
Trial: 38273019
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP) administered as a monthly, 3-days course for three consecutive months
Trial: 38273252
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen plus acetaminophen
Trial: 38273370
Drug: Consequences Of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consequences Of Screening Lung Cancer (COS-LC) questionnaire administered at prespecified timepoints including at enrolment, dependent on screening results.
Trial: 38273379
Drug: Alantel cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alantel cream (natural products at high concentrations)
Trial: 38273379
Drug: Moisturizing cream
RxNorm normalized name: MOISTURIZING CREAM
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizing cream (control)
Trial: 38273393
Drug: Titrated oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oxygen delivery targeting a blood oxygen saturation of 88-92% during inhalation therapy
Trial: 38273408
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg per day of oral CT1812 for 24 weeks
Trial: 38273408
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg per day of oral CT1812 for 24 weeks
Trial: 38273408
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg or 300 mg per day of oral CT1812 for 24 weeks
Trial: 38273617
Drug: Vagus nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus nerve stimulation (1 min once daily)
Trial: 38273617
Drug: Vagus nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus nerve stimulation (1 min four times daily)
Trial: 38273624
Drug: JNJ-55920839 (0.3-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-55920839 (0.3-15 mg/kg IV or 1 mg/kg SC)
Trial: 38279364
Drug: Otilimab 180
RxNorm normalized name: Otilimab
DrugBank: Otilimab (DB06303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otilimab 180 mg
Trial: 38273637
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg twice daily plus placebo
Trial: 38273637
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg twice daily plus methotrexate
Trial: 38273639
Drug: Sirolimus 2
RxNorm normalized name: sirolimus 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus 2 mg once daily
Trial: 38274114
Drug: 10 or
RxNorm normalized name: K-10 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 or 100 μg rTSST-1v
Trial: 38274114
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg rTSST-1v